Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Innoviva, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 20.83 · gapped above the open, then crossed back over prior close. High/low 21.05 at 7:00 am ET, 20.63 at 10:00 am ET.
Innoviva, Inc. has 10 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Innoviva, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We also entered into a Commercial Supply Agreement with Corden Pharma CHENÔVE SAS ("Corden"), under which we engaged Corden to manufacture and supply certain products related to XACDURO ® and to perform certain services and studies.”
FILING10-K0001193125-26-071776cik 0001080014
“Pursuant to the GSK Agreements, GSK is responsible for the development and commercialization of products in the partnered respiratory programs.”
FILING10-K0001193125-26-071776cik 0001080014
“We exclusively license ZEVTERA ® (pre-packaging and labeling) from Basilea for the U.S. marketing rights.”
FILING10-K0001193125-26-071776cik 0001080014
“Manufacturing of RELVAR ® /BREO ® ELLIPTA ® (FF/VI) and ANORO ® ELLIPTA ® (UMEC/VI) is performed by GSK.”
FILING10-K0001193125-26-071776cik 0001080014
“Currently, we derive the majority of our revenues from GSK and our near-term success depends in large part on GSK's ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.”
FILING10-K0001193125-26-071776cik 0001080014
“On August 11, 2025, we entered into a credit and security agreement (the "August 2025 Credit Agreement") for a loan in the aggregate amount of $15.0 million (the "August 2025 Loan") with Innoviva Sub.”
FILING10-K0001104659-26-034532cik 0000921114disclosed by ARMP
“ZEVTERA ® (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia , including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) ("Basilea") for U.S. commercialization and commercially launched in the third quarter of 2025;”
FILING10-K0001193125-26-071776cik 0001080014
“XERAVA ® is marketed in the U.S. by our wholly owned subsidiary, Tetraphase Pharmaceuticals, Inc. ("Tetraphase"), and is marketed in Europe and Great Britain by PAION on behalf of Tetraphase and is marketed in mainland China, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines by Everest Medicines Limited ("Everest").”
FILING10-K0001193125-26-071776cik 0001080014
“GIAPREZA ® is marketed in the U.S. by La Jolla and is marketed in Europe and Great Britain by PAION Deutschland GmbH, a subsidiary of the Humanwell Healthcare Group, on behalf of La Jolla.”
FILING10-K0001193125-26-071776cik 0001080014
“GIAPREZA ® is marketed in the U.S. by La Jolla and is marketed in Europe and Great Britain by PAION Deutschland GmbH, a subsidiary of the Humanwell Healthcare Group, on behalf of La Jolla.”
FILING10-K0001193125-26-071776cik 0001080014
“On December 11, 2020, we entered into the Partnership Agreement and invested $300 million of our cash reserves to be managed by Sarissa Capital as the investment manager to the Partnership.”
FILING10-K0001193125-26-071776cik 0001080014
“XERAVA ® is marketed in the U.S. by our wholly owned subsidiary, Tetraphase Pharmaceuticals, Inc. ("Tetraphase"), and is marketed in Europe and Great Britain by PAION on behalf of Tetraphase and is marketed in mainland China, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines by Everest Medicines Limited ("Everest").”
FILING10-K0001193125-26-071776cik 0001080014
“We recognized $8.0 million in license and other revenue for the year ended December 31, 2024 as a result of the achievement of a regulatory milestone under our license agreement with Zai Lab.”
FILING10-K0001193125-26-071776cik 0001080014
Watchlist prices, news filtered to it, and its next report on your desk.
INVA (Innoviva, Inc.) has 10 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ARMP −22.52%, in healthcare.